26 results about "Human feces" patented technology

The invention provides a bifidobacterium longum subsp. Longum aFMT-103 strain, which is classified and named as Bifidobacterium longum subsp. Longum, is preserved in Guangdong Microbial Culture Collection Center, and has a preservation number of GDMCC No: 65181. The invention also provides a preparation method of the bifidobacterium longum subsp. Longum aFMT-103 strain. The invention further provides a microbial preparation containing the aFMT-103 bacterial strain. In addition, the invention also provides an application of the strain or the microbial preparation in preparation of an anti-depression product, and also provides an anti-depression product. The bifidobacterium longum subsp. Longum aFMT-103 strain has the advantages that the bifidobacterium longum subsp. Longum aFMT-103 strain is separated from the faeces of healthy adults; the strain has a remarkable anti-depression effect, can be used for preparing a preparation for resisting depression symptoms, and is of great significance in prevention and adjuvant therapy of depression.

The invention relates to the technical field of biological medicine, and discloses bifidobacterium adolescentis YF-01 and application thereof in fermented milk. The bifidobacterium adolescentis YF-01 is separated from adult excrement and is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 20251308. Experiments prove that the bifidobacterium adolescentis YF-01 has good gastrointestinal fluid tolerance, the survival rate of the bifidobacterium adolescentis YF-01 can reach 90.1% after simulated gastric fluid treatment for 3 h, and the survival rate of the bifidobacterium adolescentis YF-01 can reach 72% after simulated intestinal fluid treatment for 4 h The strain has the self-aggregation rate of 88.83% and the hydrophobicity of 79.41%, has remarkable scavenging capacity on DPPH free radicals and hydroxyl free radicals, shows good antioxidant activity and adhesion capacity, and provides a theoretical basis for application of the strain in fermented milk. The strain and metabolites thereof can be used for preparing food, medicines or health care products capable of regulating intestinal flora and enhancing oxidation resistance, and have remarkable application potential in development of functional fermented milk products.

The invention discloses a strain of Bacteroides ovatus L2 and application of the strain of Bacteroides ovatus L2 in a product for preventing and treating vomitoxin toxicity. The strain is preserved in Guangdong Microbiological Culture Collection Center, the preservation number is GDMCC.No: 67205, and the preservation date is November 4, 2025. The strain is separated and purified from a healthy adult excrement sample, has the characteristics of good acid resistance, cholate resistance, gastrointestinal fluid resistance and the like, and is free of hemolysis and good in safety. The strain can effectively relieve the toxic effect induced by vomitoxin, mainly inhibits inflammatory factors and promotes expression of intestinal barrier functional proteins, can be applied to products of microecologics for preventing and treating DON toxicity, and has a good application prospect.

Disclosed herein are methods for administering a dose of a microbiota recovery therapy composition by colonoscopy. The methods disclosed herein are useful for the treatment of diseases and / or conditions of the digestive tract, such as Clostridium difficile infection (GDI), including recurrent GDI, and other gastrointestinal disorders. The method can result in improved quality of life. These methods are capable of altering the gut microbiota composition and / or the gut metabolome composition. The microbiota recovery therapy composition comprises a fecal microbiota suspension comprising: a fecal microorganism derived from a human fecal sample, and a solution of polyethylene glycol and brine.

The present disclosure provides freeze-dried and liquid compositions that include an extract of human feces. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's intestinal microbiota, and methods for treating a disease or condition such as hepatic encephalopathy.

The invention relates to the technical field of medicines, and discloses a bifidobacterium longum strain GZBAI 01 and application thereof in degradation of benzoic acid and prevention or treatment of colorectal cancer. The strain is separated from faeces of healthy people, genomics identification is carried out, the metabolic profile of the strain is measured through metabonomics, the strain can convert benzoic acid with carcinogenic risk into protocatechuic acid with antitumor activity through unique metabolic capability, meanwhile, the function of regulatory T cells (Treg) in tumor drainage lymph nodes can be inhibited, differentiation of CD8 + T cells is promoted, and the tumor drainage lymph nodes can be inhibited. Therefore, the colorectal cancer is prevented through double ways of eliminating cancerogen and generating therapeutic agents. A colorectal cancer mouse model and a subcutaneous tumor mouse model verify that the strain can significantly reduce the number and volume of tumors, and shows a benzoic acid conversion effect superior to that of other strains in vivo and in vitro, and a new way is provided for prevention and treatment of colorectal cancer.

The invention provides a simulated excrement sample for radioactive bioassay and application of the simulated excrement sample. The simulated excrement sample comprises inorganic components and organic components. The simulated excrement sample is close to real human excrement in composition, physicochemical properties and biological activity, nuclides are uniformly distributed in the simulated excrement sample and can be stored for a long time, and a reliable research tool can be provided for radioactive bioassay, especially in the fields of drug research and development, environmental monitoring and the like.

The present application belongs to the technical field of microbial inoculants, and particularly relates to a Phocaediola doleeri, and further discloses a use of the Phocaediola doleeri in preparing a product for preventing and treating glycolipid metabolic disorder. A YG0564 strain is screened from healthy adult feces, and is identified as the Phocaediola doleeri and classified and named as Phocaediola doleeri. The Phocaediola doleeri strain YG0564 contains cholesteryl sulfatase, and can significantly reduce blood fat and blood sugar in vivo and in vitro, and can obviously prevent and treat obesity and glycolipid metabolic disorder.

The invention provides a method for simultaneously determining the contents of various short-chain fatty acids in human excrement, and innovatively develops an artificial excrement simulated blank matrix and a related detection system in order to solve the industrial problem that an effective blank matrix is lacked in excrement short-chain fatty acid (SCFAs) detection. The blank matrix is composed of a diluent, a microbial structure simulation agent and a fiber matrix skeleton, the problem of natural matrix deficiency is solved, and high-throughput, standardized and accurate quantitative analysis of the SCFAs in the excrement is achieved. A calibration curve is constructed on the basis of the matrix, synchronous and accurate quantification of the SCFAs in the excrement including acetic acid, propionic acid, butyric acid and the like is realized by combining a 3-NPH / EDC-pyridine derivatization LC-MS / MS technology, the recovery rate of the method is as high as 92.6%-111.2%, and the matrix effect deviation is stabilized to be smaller than or equal to + / -5%. The matched kit integrates the blank matrix, an SCFAs standard substance, a butyric acid-d7 internal standard and a derivatization reagent, and provides a standardized detection process. According to the achievement, the accuracy (RSD is less than or equal to 5%) of excrement SCFAs detection is remarkably improved, and the technical blank in the field is effectively filled.

The present invention concerns a Parabacteroides distasonis strain deposited under accession number CNCM I-5828. This strain can be useful in multiple applications, in particular incorporated in a nutritional supplement or in a composition for use as a medicament, especially in the prevention or treatment of visceral pain, preferably induced by Inflammatory Bowel Disease including Crohn's disease and Ulcerative Colitis, or by Irritable Bowel Syndrome.

The invention discloses a detection kit for detecting calprotectin in human excrement, the detection kit is composed of a sample diluent and detection test paper, the detection test paper is composed of a bottom plate, a nitrocellulose membrane, a conjugate pad, a sample pad and absorbent paper, the absorbent paper, the nitrocellulose membrane, the conjugate pad and the sample pad are sequentially overlapped on the bottom plate, a shell is arranged outside the detection test paper, and the shell is connected with the sample pad. An observation window and a sample adding hole are formed in the shell, and the position of the observation window is matched with the position of the nitrocellulose membrane; the position of the sample adding hole is matched with the position of the sample pad; the nitrocellulose membrane is sequentially provided with a T1 detection line coated with an anti-calprotectin monoclonal antibody, a T2 detection line coated with an anti-calprotectin monoclonal antibody and a quality control line C coated with a goat anti-chicken IgY antibody and / or a goat anti-mouse IgG antibody; a calprotectin monoclonal antibody marked by colloidal gold is solidified on the combination pad, and the sample diluent is prepared from sodium chloride, EDTA (Ethylene Diamine Tetraacetic Acid), PEG (Polyethylene Glycol) 20000, Proclin-300 and purified water.

The invention provides a structural bacteria-based stone flora pharmaceutical composition. The structural bacteria-based stone flora pharmaceutical composition is prepared from live bacteria of bifidobacterium pseudominum aFMT-202, live bacteria of bifidobacterium longum subsp. Longum aFMT-104 and live bacteria of lactobacillus mucosa aFMT-501. The invention also provides a microbial medicinal preparation and a preparation method thereof, and also provides application of the composition in preparation of antidepressant drugs, intestinal anti-inflammatory drugs and antioxidant and anti-aging drugs. The three strains are separated from faeces of healthy adults, have acid resistance, bile salt resistance and intestinal epithelium adhesion capacity, can regulate neurotransmitter balance, enhance intestinal mucosal barrier and up-regulate endogenous antioxidant enzyme activity respectively, have complementary functions and are free of drug resistance and pathogenicity; the composition forms a composite preparation according to a specific ratio, can intervene in depression, chronic intestinal inflammation and aging-related functional decline, solves the limitation that the existing single-target medicine takes effect slowly, has large side effects and cannot intervene comprehensively, and overcomes the defect of clinical multi-target collaborative treatment.

The utility model relates to the technical field of human excrement treatment equipment, in particular to an exhaust device of a fermentation bin, which comprises a fermentation bin cover, the fermentation bin cover comprises an exhaust port, and the exhaust device further comprises an exhaust fan arranged in the exhaust port; the filter screen is arranged in the exhaust port and located on the air inlet side of the exhaust fan, so that waste impurities in the fermentation bin are prevented from directly entering the exhaust fan in the exhaust process, and the service life of the exhaust fan is effectively prolonged.

The invention relates to application of common bacteroides in reducing blood sugar. Specifically, the invention provides a common bacteroides J2525 with a hypoglycemic function, the bacteroides is a gram-negative bacterium separated and purified from human excrement, the bacteroides is preserved in the China General Microbiological Culture Collection Center (CGMCC) on April 25, 2025, the preservation number is CGMCC NO.46398, the preservation number is CGMCC NO.46398, the preservation number is CGMCC NO.46398, and the preservation number is CGMCC NO.46398. The invention further provides a preparation method of the bacteroides J2525. The invention further provides a preparation method of the bacteroides J2525. The invention further provides a preparation method of the bacteroides J2525 with the hypoglycemic function and application of the bacteroides J2525 with the hypoglycemic function. The invention also provides application of the common bacteroides J2525 in preparation of products for reducing blood sugar, improving glucose tolerance or improving insulin sensitivity. The invention shows that the common bacteroid strain J2525 can be developed as a probiotic with a good hypoglycemic effect, and has a high reference value for clinical application of the strain.

The invention discloses humanized lactobacillus johnsonii MYR-117 and application thereof, the preservation number of the humanized lactobacillus johnsonii MYR-117 is GDMCC No: 65346, the humanized lactobacillus johnsonii MYR-117 is separated and identified from a faeces sample of a healthy person, and a mouse myelosuppression model is further combined to find that the lactobacillus johnsonii can resist myelosuppression induced by cyclophosphamide, so that the lactobacillus johnsonii MYR-117 can be used for resisting myelosuppression induced by cyclophosphamide; the levels of white blood cells, hemoglobin, platelets and red blood cells can be increased, bone marrow cell apoptosis is reduced, the thighbone marrow form is recovered, and the bone marrow hematopoietic capacity is Therefore, the compound can be used for preparing anti-myelosuppression drugs, leukocyte increasing drugs, erythrocyte increasing drugs, chemotherapy adjuvant therapy drugs and health-care products. Meanwhile, as the lactobacillus johnsonii is edible probiotics, the lactobacillus johnsonii can be used for preparing health-care food.

The present application relates to a kind of Bacteroides in lowering blood sugar. Specifically, the present application provides a kind of Bacteroides plebeius J2525 with the function of lowering blood sugar, which is a strain of gram-negative bacteria isolated and purified from human feces, which has been preserved in China General Microbiological Culture Collection Center (CGMCC) on April 25, 2025, and the preservation number is CGMCC NO.46398. The present application also provides the use of Bacteroides plebeius J2525 of the present application in the preparation of products for lowering blood sugar, improving glucose tolerance or improving insulin sensitivity. The present application shows that Bacteroides plebeius strain J2525 can be developed as a kind of probiotics with good blood sugar lowering effect, and has high reference value for the application of the strain in clinic.

The application discloses an intestinal flora regulator containing unsaturated oligogalacturonic acid and application thereof, and an effective component of the intestinal flora regulator containing unsaturated oligogalacturonic acid comprises lemon unsaturated oligogalacturonic acid with a molecular weight of 80-85 kDa and an unsaturation degree of 7-10. The application finds that the intestinal flora regulator containing unsaturated oligogalacturonic acid has a regulating effect on intestinal flora by simulating an in-vivo environment in vitro and collecting intestinal microorganisms in human feces, including regulating the abundance, structure and diversity of intestinal flora, promoting the proliferation of beneficial bacteria such as bifidobacterium and lactobacillus, and inhibiting the proliferation of escherichia shigella and bacteroides, and can provide help for the development of intestinal disease treatment drugs.

The present disclosure provides freeze-dried compositions that include an extract of human feces and a flavoring agent, where the compositions, upon reconstitution with a liquid, have no objectionable odor and has no objectionable taste. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease. In some embodiments, the subject can be an individual with reduced ability to swallow, such as pill dysphagia, or an individual refractory to administration of a liquid having an objectionable odor or objectionable taste.

This invention discloses a method and application for preparing Renzhonghuang (a traditional Chinese medicine) from licorice using artificially synthesized bacterial cultures through fermentation. It belongs to the field of traditional Chinese medicine preparation technology. The method involves analyzing the dominant probiotic flora in healthy human fecal samples using metagenomic sequencing, screening out 15 representative intestinal probiotic strains, and constructing an artificially synthesized bacterial culture based on their relative abundance ratios in the natural gut. Licorice powder is mixed with a suspension of the artificially synthesized bacterial culture, and fermented at 37°C to prepare Renzhonghuang. The resulting Renzhonghuang is stable in quality and has high safety. Pharmacological experiments have confirmed that its anti-H1N1 influenza virus effect is superior to that of Renzhonghuang produced using traditional methods, significantly reducing viral load, inflammatory factor levels, and lung index in lung tissue, and improving lung pathological damage. This invention eliminates the unclean process of traditional cesspool fermentation, achieving standardized, controllable, and industrialized production of Renzhonghuang, and has significant clinical application value and market prospects.

The invention discloses a mobile house structure capable of saving energy, reducing emission and switching an office and a bedroom. The mobile house structure comprises an office and bedroom switching room, a kitchen, a toilet, a balcony, an interlayer room, a solar cell panel, a power source and a water well. The solar cell panel is installed on an inclined roof of the mobile house and used for generating electricity and storing electricity into a power source, electricity of the house is conveyed by the power source, a water well provides domestic water and conveys fresh air, cold air is supplied in summer, warm air is supplied in winter, a closet pan, a urinal and a floor drain are arranged in a toilet, and human excrement and urine are separately discharged into different sewage pools through pipes. Excrement of the closet pan is discharged into the septic tank, urine of the urinal is discharged into the urine storage tank, the urine permeates into vegetable planting soil, sewage of the septic tank is conveyed to a fruit field, a toilet and a kitchen through an automobile, floor drain sewage is discharged into a toilet sewage tank and treated by a sewage filter to become recycled water, and the recycled water is sprayed on a road for dust prevention and is turned into solid organic fertilizer in the kitchen sewage tank. The method comprises the following steps: putting human food residual fish, meat and animal viscera organic garbage into a freezer, freezing into solid vegetable organic garbage, packaging with an organic fiber bag, crushing into residues by a garbage processor, stirring the vegetable residues and the animal viscera organic garbage with organic soil to obtain solid fertilizer, processing inorganic garbage into natural aggregate, and carrying out centralized outward transportation treatment.

The present invention discloses a strain of Lactobacillus casei for warming the uterus and dispelling cold and improving mammary gland health and its postbiotics, belonging to the field of microbial application technology. The present invention isolates a strain of Lactobacillus casei (Lacticaseibacillus casei) WZA-LC26 from human feces, and its biological preservation number is: CCTCC NO: M20241410. The present invention screens out a strain of Lactobacillus casei for warming the uterus and dispelling cold and improving mammary gland health, and combines its postbiotics with medicinal and edible substances, creating a natural and efficient health conditioning program that treats both the symptoms and the root causes. Through this combination, not only can the effects of Chinese medicine such as warming the meridians and dispelling cold, promoting blood circulation and removing blood stasis, and soothing the liver and relieving depression be fully utilized, but also the multi-target effects of postbiotics such as immune regulation, anti-inflammatory and antioxidant, and promoting endocrine balance can be used to significantly improve the efficacy and safety of the drug.

The invention discloses Lactobacillus salivarius NCU-41 and application thereof, and belongs to the field of microbial medicines.The strain is a new strain which is screened from faeces of healthy people and has the activity of preventing and / or relieving Parkinson's disease, and the strain is gram-positive bacillus-free, has no hemolytic activity and no cytotoxicity, meets the safety standard of probiotics, and can be used for preparing probiotics for preventing and / or relieving Parkinson's disease. The lactobacillus salivarius NCU-41 can be applied for a long time through an oral preparation, so that side effects such as liver and kidney injury and gastrointestinal tract reaction caused by treating Parkinson's disease through chemical drugs are avoided, and a mechanism that the lactobacillus salivarius NCU-41 and the metabolite of the lactobacillus salivarius NCU-41 enhance the anti-oxidation defense capability in the brain by activating an AKT / Nrf2 signal channel is further researched and clarified.

The invention discloses a culture medium and a culture method for culturing human intestinal flora in vitro, every 1000g of the culture medium contains 5-20g of casein tryptone, 1-10g of beef extract, 1-10g of soybean oligosaccharide, 0.1-1g of monopotassium phosphate, 1-15g of sodium chloride, 0.5-5mg of hemin, 1-5g of cysteine hydrochloric acid, 0.5-2g of cholate, 20-100g of microcrystalline cellulose and 1-5g of agar powder, water is added to fix the volume to 1000mL, and the pH value is adjusted to 6.0-7.5. And after high-temperature steam sterilization, cooling to 40 DEG C, adding 0.5-5 / 1000 (V / V) serum, and uniformly mixing. The invention provides a culture medium and a culture method capable of culturing flora growth in human excrement twice through passage. In-vitro culture similar to intestinal flora characteristics of healthy donors is successfully realized, so that an ideal intestinal bacteria product is provided for intestinal bacteria transplantation treatment.

This invention provides a strain of *Bacteroides vulgaris* and its uses. Specifically, this invention isolates for the first time a strain of *Bacteroides vulgaris* capable of producing 3-indolepropionic acid from human feces, which was deposited on April 25, 2025, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC NO.46398. Furthermore, this invention provides the application of the *Bacteroides vulgaris* described herein in the production of 3-indolepropionic acid. Even further, this invention provides a method for producing 3-indolepropionic acid using the *Bacteroides vulgaris* described herein, and the application of the *Bacteroides vulgaris* described herein in increasing the content of 3-indolepropionic acid in the body.

The present application belongs to the technical field of microbial inoculants, and particularly relates to a Bifidobacterium lactis, and further discloses a use of the Bifidobacterium lactis in preparation of an anti-obesity product and / or a weight loss product. A YG2013 strain is screened from healthy adult feces, and is identified as the Bifidobacterium lactis and classified as Bifidobacterium lactis. According to experimental identification, the Bifidobacterium lactis YG2013 strain can realize white adipose beige and activate brown adipose metabolism heat production through targeted regulation of tgr5 / Il-27, so as to achieve the effect of efficient weight loss, and has a good effect of treating weight loss and weight loss.

Disclosed herein are methods for administering a dose of a microbiota restoration therapy composition by colonoscopy. The methods disclosed herein are useful for treating diseases and / or conditions of the digestive tract, such as Clostridioides difficile infection (GDI), including recurrent GDI, and other gastrointestinal disorders. The method may result in improved quality of life. The methods may alter gut microbiota composition and / or gut metabolome composition. The microbiota restoration therapy composition comprises a fecal microbiota suspension comprising: fecal microbes derived from a human fecal sample, and a solution of polyethylene glycol and saline.